An 8-year-old boy living in a town outside Glasgow, Scotland, experienced a frightening bacterial meningitis epidemic in which five of his best friends died, one of his friends lost his hearing in both ears, and the young boy lost his sight completely in one eye and partially in the second eye. This young boy was why I became an ophthalmologist and why I continually participate in clinical trials to find new ways to improve care for our patients both medically and surgically. This young boy was my father, who in (Read more...)
Femtosecond laser superior in creating capsulorrhexis
LONDON – One of the original users of femtosecond laser for cataract surgery, Zoltan Nagy, MD, says that femtosecond laser is superior in creating capsulotomy in terms of size, centration and geometry.At the European Society of Cataract and Refractive Surgeons meeting here, Nagy also discusses barriers to wider adoption of femtosecond laser cataract surgery.
Personalised treatment on horizon for rare genetic disease patients
UK researchers have identified the most serious genetic mutations responsible for a rare condition that causes blindness, opening the door for personalised treatment and tailored gene therapies.
Risk of glaucoma doubles at 5 years after PRK
LONDON – A study shows the risk of developing glaucoma doubles at 5 years following photorefractive keratotomy, according to a glaucoma specialist here. Marco Nardi, MD, discusses his study looking at glaucoma indicators following PRK here at the European Society of Cataract and Refractive Surgeons meeting.
Suggested change to patient care after glaucoma laser surgery
New research led by Queen’s University professor Robert Campbell (Ophthalmology) has revealed using anti-inflammatory medications after glaucoma laser surgery is not helpful or necessary.
Acufocus introduces depth of focus IOL
LONDON – Acufocus Chairman and CEO James V. Mazzo discusses the company’s launch of the Acufocus IC‐8 small aperture IOL, which utilizes the same pinhole effect as the Kamra intracorneal inlay. The lens received CE mark approval September 11. The company plans a slow commercial launch in Europe in while they perform a post-market approval study. The IC‐8 IOL is not approved for use in the United States.